These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 36831406)

  • 1. Protein Signatures and Individual Circulating Proteins, including IL-6 and IL-15, Associated with Prognosis in Patients with Biliary Tract Cancer.
    Christensen TD; Madsen K; Maag E; Larsen O; Jensen LH; Hansen CP; Markussen A; Høgdall DTS; Chen IM; Nielsen D; Johansen JS
    Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and validation of circulating protein signatures as diagnostic biomarkers for biliary tract cancer.
    Christensen TD; Maag E; Larsen O; Feltoft CL; Nielsen KR; Jensen LH; Leerhøy B; Hansen CP; Chen IM; Nielsen DL; Johansen JS
    JHEP Rep; 2023 Mar; 5(3):100648. PubMed ID: 36699667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blood-based tumor fibrosis markers as diagnostic and prognostic biomarkers in patients with biliary tract cancer.
    Christensen TD; Jensen C; Larsen O; Leerhøy B; Hansen CP; Madsen K; Høgdall D; Karsdal MA; Chen IM; Nielsen D; Johansen JS; Willumsen N
    Int J Cancer; 2023 Mar; 152(5):1036-1049. PubMed ID: 36455598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum immuno-oncology markers carry independent prognostic information in patients with newly diagnosed metastatic breast cancer, from a prospective observational study.
    Gunnarsdottir FB; Bendahl PO; Johansson A; Benfeitas R; Rydén L; Bergenfelz C; Larsson AM
    Breast Cancer Res; 2023 Mar; 25(1):29. PubMed ID: 36945037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of preoperative inflammatory markers in resectable biliary tract cancer - Validation and comparison of the Glasgow Prognostic Score and Modified Glasgow Prognostic Score in a Western cohort.
    Jansson H; Cornillet M; Björkström NK; Sturesson C; Sparrelid E
    Eur J Surg Oncol; 2020 May; 46(5):804-810. PubMed ID: 31848078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating levels of soluble urokinase plasminogen activator receptor predict outcome after resection of biliary tract cancer.
    Loosen SH; Breuer A; Tacke F; Kather JN; Gorgulho J; Alizai PH; Bednarsch J; Roeth AA; Lurje G; Schmitz SM; Brozat JF; Paffenholz P; Vucur M; Ritz T; Koch A; Trautwein C; Ulmer TF; Roderburg C; Longerich T; Neumann UP; Luedde T
    JHEP Rep; 2020 Apr; 2(2):100080. PubMed ID: 32140677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dynamics of Soluble Programmed Death-Ligand 1 (sPDL1) during Chemotherapy and Its Prognostic Implications in Cancer Patients: Biomarker Development in Immuno-oncology.
    Ha H; Bang JH; Nam AR; Park JE; Jin MH; Bang YJ; Oh DY
    Cancer Res Treat; 2019 Apr; 51(2):832-840. PubMed ID: 30309223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble programmed death-ligand 1 (sPDL1) and neutrophil-to-lymphocyte ratio (NLR) predicts survival in advanced biliary tract cancer patients treated with palliative chemotherapy.
    Ha H; Nam AR; Bang JH; Park JE; Kim TY; Lee KH; Han SW; Im SA; Kim TY; Bang YJ; Oh DY
    Oncotarget; 2016 Nov; 7(47):76604-76612. PubMed ID: 27780932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum IL6 as a Prognostic Biomarker and IL6R as a Therapeutic Target in Biliary Tract Cancers.
    Høgdall D; O'Rourke CJ; Dehlendorff C; Larsen OF; Jensen LH; Johansen AZ; Dang H; Factor VM; Grunnet M; Mau-Sørensen M; Oliveira DVNP; Linnemann D; Boisen MK; Wang XW; Johansen JS; Andersen JB
    Clin Cancer Res; 2020 Nov; 26(21):5655-5667. PubMed ID: 32933994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. N-glycan signatures identified in the serum from biliary tract cancer patients: Association with clinical diagnosis and prognosis.
    Huang C; Qiu Z; Wang M; Ji J; Xiao X; Wang Y; Xu X; Gao Z; Gao C
    J Hepatobiliary Pancreat Sci; 2024 Aug; 31(8):537-548. PubMed ID: 38824438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma proteins associated with cardiovascular death in patients with chronic coronary heart disease: A retrospective study.
    Wallentin L; Eriksson N; Olszowka M; Grammer TB; Hagström E; Held C; Kleber ME; Koenig W; März W; Stewart RAH; White HD; Åberg M; Siegbahn A
    PLoS Med; 2021 Jan; 18(1):e1003513. PubMed ID: 33439866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutrophil/lymphocyte ratio as a prognostic factor in biliary tract cancer.
    McNamara MG; Templeton AJ; Maganti M; Walter T; Horgan AM; McKeever L; Min T; Amir E; Knox JJ
    Eur J Cancer; 2014 Jun; 50(9):1581-9. PubMed ID: 24630393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic factors in patients with advanced biliary tract cancer treated with first-line gemcitabine plus cisplatin: retrospective analysis of 740 patients.
    Kim BJ; Hyung J; Yoo C; Kim KP; Park SJ; Lee SS; Park DH; Song TJ; Seo DW; Lee SK; Kim MH; Park JH; Cho H; Ryoo BY; Chang HM
    Cancer Chemother Pharmacol; 2017 Jul; 80(1):209-215. PubMed ID: 28597043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic Factors in Patients Treated with Pembrolizumab as a Second-Line Treatment for Advanced Biliary Tract Cancer.
    Park CS; Sung MJ; Kim SJ; Jo JH; Lee HS; Chung MJ; Bang S; Park SW; Song SY; Park JY
    Cancers (Basel); 2022 Sep; 14(17):. PubMed ID: 36077857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating Protein Biomarkers for Prognostic Use in Patients with Advanced Pancreatic Ductal Adenocarcinoma Undergoing Chemotherapy.
    Lindgaard SC; Maag E; Sztupinszki Z; Chen IM; Johansen AZ; Jensen BV; Bojesen SE; Nielsen DL; Szallasi Z; Johansen JS
    Cancers (Basel); 2022 Jul; 14(13):. PubMed ID: 35805022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Whole blood microRNAs capture systemic reprogramming and have diagnostic potential in patients with biliary tract cancer.
    Høgdall D; O'Rourke CJ; Larsen FO; Zarforoushan S; Christensen TD; Ghazal A; Boisen MK; Muñoz-Garrido P; Johansen JS; Andersen JB
    J Hepatol; 2022 Oct; 77(4):1047-1058. PubMed ID: 35750139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101.
    Chiorean EG; Ramasubbaiah R; Yu M; Picus J; Bufill JA; Tong Y; Coleman N; Johnston EL; Currie C; Loehrer PJ
    Oncologist; 2012; 17(1):13. PubMed ID: 22210086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preoperative immunological plasma markers TRAIL, CSF1 and TIE2 predict survival after resection for biliary tract cancer.
    Jansson H; Cornillet M; Sun D; Filipovic I; Sturesson C; O'Rourke CJ; Andersen JB; Björkström NK; Sparrelid E
    Front Oncol; 2023; 13():1169537. PubMed ID: 37404757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-life analysis of treatment approaches and the role of inflammatory markers on survival in patients with advanced biliary tract cancer.
    Goktas Aydin S; Cakan Demirel B; Bilici A; Topcu A; Aykan MB; Kahraman S; Akbıyık I; Atci MM; Olmez OF; Yaren A; Sendur MAN; Geredeli C; Seker M; Urun Y; Karadurmus N; Aydin A
    Curr Med Res Opin; 2022 Oct; 38(10):1751-1758. PubMed ID: 35916475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prognostic role of soluble transforming growth factor-β and its correlation with soluble programmed death-ligand 1 in biliary tract cancer.
    Kim JW; Lee KH; Kim JW; Suh KJ; Nam AR; Bang JH; Jin MH; Oh KS; Kim JM; Kim TY; Oh DY
    Liver Int; 2021 Feb; 41(2):388-395. PubMed ID: 32780918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.